Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes-Reference-Cited by-同舟云学术

Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes

Published:2020-02-01 Issue:2 Volume:6 Page:206
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Terrisse Safae¹²³,Karamouza Eleni²⁴,Parker Chris C.⁵⁶,Sartor A. Oliver⁷,James Nicholas D.⁸,Pirrie Sarah⁸,Collette Laurence⁹,Tombal Bertrand F.¹⁰,Chahoud Jad¹¹,Smeland Sigbjørn¹²,Erikstein Bjørn¹²,Pignon Jean-Pierre²⁴¹³,Fizazi Karim¹²,Le Teuff Gwénaël²⁴¹³,

Affiliation:

1. Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France

2. Université Paris Sud, Orsay, France

3. INSERM U1015, Université Paris Sud, Orsay, France

4. Ligue Nationale Contre le Cancer Meta-Analysis Platform, Biostatistics and Epidemiology Unit, Institut Gustave Roussy, Villejuif, France

5. The Royal Marsden NHS Foundation Trust, London, United Kingdom

6. Institute of Cancer Research, Sutton, United Kingdom

7. Tulane University School of Medicine, New Orleans, Louisiana

8. Institute of Cancer and Genomic Sciences, University Hospitals Birmingham, Birmingham, United Kingdom

9. European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium

10. Cliniques Universitaires Saint Luc, Brussels, Belgium

11. The University of Texas MD Anderson Cancer Center, Houston

12. Division of Cancer Medicine, Oslo University Hospital, University of Oslo, Oslo, Norway

13. CESP, Faculté de médecine, Université Paris Sud, Faculté de médecine, INSERM U1018, Université Paris Saclay, Villejuif, France

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2757384/jamaoncology_terrisse_2019_oi_190083.pdf

Reference34 articles.

1. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018.;Ferlay;Eur J Cancer,2018

3. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.;Tannock;N Engl J Med,2004

4. Abiraterone and increased survival in metastatic prostate cancer.;de Bono;N Engl J Med,2011

5. Increased survival with enzalutamide in prostate cancer after chemotherapy.;Scher;N Engl J Med,2012

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in the development of radiopharmaceuticals for nuclear medicine applications in the treatment of bone metastases;Nuclear Medicine and Biology;2024-03

2. The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease;Journal of Nuclear Medicine;2024-02-15

3. A New Immunotherapy Combination Promises to Improve Survival for Patients with Metastatic Prostate Cancer;Cancers;2023-11-29

4. Recent Advancement of Bio-Inspired Nanoparticles in Cancer Theragnostic;Journal of Nanotheranostics;2023-07-24